⬡NOVALYTELABS
COMPOUND COMPARISON

CJC-1295 (with DAC) vs Ipamorelin

Two growth hormone secretagogues that work on opposite halves of the same axis.

The short answer: CJC-1295 amplifies the size of GH pulses; ipamorelin triggers them.

Side by side

PropertyCJC-1295 (with DAC)Ipamorelin
Research categoryGrowth ResearchGrowth Research
Presentation5mg vial10mg vial
Dosage options5mg10mg
Approved medicine using itNone — investigationalNone — investigational
AvailabilityLow stockIn stock
Batch COASupplied with orderSupplied with order
From€99.00€42.90

How they differ

Growth hormone release is governed by two opposing signals: GHRH, which stimulates, and somatostatin, which inhibits. These two compounds enter that system at different points.

CJC-1295 is a GHRH analog. It acts on the GHRH receptor and is associated with increased amplitude of existing pulses. Ipamorelin is a ghrelin mimetic acting on the GHS-R receptor, associated with initiating pulses and with a selectivity that distinguishes it from earlier secretagogues in the class.

Because one raises pulse height and the other pulse frequency, they are complementary rather than competing — the reason they appear together in so much of the literature.

At the bench

Both are lyophilised and both are typically prepared at small doses, which puts them squarely in the range where a 0.3 ml barrel reads more reliably than a 1 ml one. Because they act at different points of the same axis, they are usually studied together rather than compared.

What this comparison does not settle

Describing one as raising pulse amplitude and the other pulse frequency simplifies a feedback system that also involves somatostatin. The interaction between the two is not simply additive.

Common questions

What is the difference between CJC-1295 (with DAC) and Ipamorelin?

CJC-1295 amplifies the size of GH pulses; ipamorelin triggers them. Two growth hormone secretagogues that work on opposite halves of the same axis.

Is CJC-1295 (with DAC) or Ipamorelin better?

Neither, and the question does not have a general answer. They are compared here on mechanism rather than merit. Describing one as raising pulse amplitude and the other pulse frequency simplifies a feedback system that also involves somatostatin. The interaction between the two is not simply additive.

Which of the two has more published data?

Neither has an approved formulation — both are investigational, and the published work on each is correspondingly narrower.

For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use. Brand names are trademarks of their respective owners and are referenced only to identify the active compound — no affiliation or equivalence is claimed.